{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:39:52Z","timestamp":1770478792822,"version":"3.49.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1993,6,1]],"date-time":"1993-06-01T00:00:00Z","timestamp":738892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Metast Rev"],"published-print":{"date-parts":[[1993,6]]},"DOI":"10.1007\/bf00689809","type":"journal-article","created":{"date-parts":[[2004,11,30]],"date-time":"2004-11-30T16:16:29Z","timestamp":1101831389000},"page":"177-193","source":"Crossref","is-referenced-by-count":19,"title":["Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference toin vivo methods of evaluation"],"prefix":"10.1007","volume":"12","author":[{"given":"Jane C. M.","family":"Bremner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1259\/0007-1285-51-611-888","volume":"51","author":"S Dische","year":"1979","unstructured":"Dische S: Hyperbaric oxygen: the medical Research Council Trials and their clinical significance. Br J Radiol 51: 888?894, 1979","journal-title":"Br J Radiol"},{"key":"CR2","first-page":"181","volume-title":"Cancer: a comprehensive treatise","author":"GE Adams","year":"1977","unstructured":"Adams GE: Hypoxic cell radiosensitizers for radiotherapy. In: Becker F (ed) Cancer: a comprehensive treatise. Vol. 6. Plenum Press, New York, 1977, pp181?223"},{"key":"CR3","first-page":"3501","volume":"34","author":"RM Sutherland","year":"1974","unstructured":"Sutherland RM: Selective chemotherapy of non-cycling cells in anin vitro tumor model. Cancer Res 34: 3501?3503, 1974","journal-title":"Cancer Res"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-46-543-234","volume":"46","author":"JL Foster","year":"1973","unstructured":"Foster JL, Willson RL: Radiosensitization of anoxic cells by metronidazole. Br J Radiol 46: 234?235, 1973","journal-title":"Br J Radiol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-2952(80)90235-X","volume":"29","author":"KA Kennedy","year":"1980","unstructured":"Kennedy KA, Teicher BA, Rockwell S, Sartorelli AC: The hypoxic tumour cell: a target for selective cancer chemotherapy. Biochem Pharmac 29: 1?8, 1980","journal-title":"Biochem Pharmac"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/bjc.1984.91","volume":"49","author":"GE Adams","year":"1984","unstructured":"Adams GE, Ahmed I, Sheldon PW, Stratford IJ: Radiation sensitization and chemopotentiation: RSU1069 a compound more efficient than misonidazolein vitro andin vivo. Br J Cancer 49: 571?578, 1984","journal-title":"Br J Cancer"},{"key":"CR7","first-page":"3642","volume":"45","author":"SR Keyes","year":"1985","unstructured":"Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sligar SG, Sartorelli AC: Chemotherapeutic attack of hypoxic cells by the bioreductive agent, mitomycin-C. Cancer Res 45: 3642?3645, 1985","journal-title":"Cancer Res"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/0360-3016(86)90267-1","volume":"12","author":"EM Zeman","year":"1986","unstructured":"Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW: SR4233, a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12: 1239?1242, 1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0360-3016(89)90898-5","volume":"16","author":"IJ Stratford","year":"1989","unstructured":"Stratford IJ, Stephens MA: The differential hypoxic cytotoxicity of bioreductive agents determinedin vitro by the MTT assay. Int J Radiat Oncol Biol Phys 16: 973?976, 1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-1-4615-3768-7_16","volume-title":"Selective activation of drugs by redox processes","author":"P Workman","year":"1990","unstructured":"Workman P, Walton MI: Enzyme related bioreductive drug development. In: Adams GE, Breccia A, Fielden EM, Wardman P (eds) Selective activation of drugs by redox processes. Plenum Press, New York, 1990, pp173?191"},{"key":"CR11","first-page":"103","volume-title":"Modification of radiosensitivity of biological systems","author":"GE Adams","year":"1976","unstructured":"Adams GE, Fowler JF: Nitroimidazoles as hypoxic cell sensitizersin vitro andin vivo. In: Modification of radiosensitivity of biological systems. I.A.E.A. Vienna, 1976, pp103?117"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2307\/3578516","volume":"132","author":"GE Adams","year":"1992","unstructured":"Adams GE: Redox, radiation and reductive bioactivation. Radiat Res 132: 129?139, 1992","journal-title":"Radiat Res"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2307\/3574010","volume":"60","author":"JC Asquith","year":"1974","unstructured":"Asquith JC, Watts ME, Patel K, Smithen CE, Adams GE: Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cellsin vitro by some nitroimidazoles and nitropyrazoles. Radiat Res 60: 108?118, 1974","journal-title":"Radiat Res"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0009-9260(76)80138-9","volume":"27","author":"S Dische","year":"1976","unstructured":"Dische S, Gray AJ, Zanelli GD: Clinical testing of the radiosensitizer Ro-07-0582. II. Radiosensitization of normal and hypoxic skin. Clin Radiol 27: 159?166, 1976","journal-title":"Clin Radiol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0009-9260(76)80137-7","volume":"27","author":"AJ Gray","year":"1976","unstructured":"Gray AJ, Dische S, Adams GE, Flockhart IR, Foster JL: Clinical testing of the radiosensitizer Ro-07-0582. I. Dose, tolerance, serum and tumor concentrations. Clin Radiol 27: 151?157, 1976","journal-title":"Clin Radiol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0009-9260(76)80139-0","volume":"27","author":"RH Thomlinson","year":"1976","unstructured":"Thomlinson RH, Dische S, Gray AJ, Errington LM: Clinical testing of the radio sensitizer Ro-07-0582. III. Response of tumours. Clin Radiol 27: 167?174, 1976","journal-title":"Clin Radiol"},{"key":"CR17","first-page":"137","volume-title":"Progress in radio-oncology III, Proceedings of the 3rd International Meeting on Progress in Radio-oncology, March 1985","author":"J Overgaard","year":"1987","unstructured":"Overgaard J, Hansen SH, Anderson AP, Hjelm-Handsen M, Jorgensen K, Sandberg K, Rygard J, Jensen RH, Peterson M: Misonidazole as an adjunct to radiotherapy in the treatment of invasive carcinoma of the larynx and pharynx. In: Karcher KH, Kogelnik HD, Szepesi T (eds) Progress in radio-oncology III, Proceedings of the 3rd International Meeting on Progress in Radio-oncology, March 1985. I.C.R.O., Vienna, 1987, pp137?147"},{"key":"CR18","first-page":"83","volume-title":"Radiation Sensitizers. Cancer Management","author":"P Wardman","year":"1980","unstructured":"Wardman P, Clarke ED, Jacobs RS, Minchinton A, Stratford MRL, Watts ME, Woodcock M, Moazzam M, Parrick J, Wallace RG, Smithen CE: Development of hypoxic cell radiosensitizers. The second and third generations. In: Brady LW (ed) Radiation Sensitizers. Cancer Management, Vol 5. Masson Publishing, USA, 1980, pp83?90"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2307\/3574491","volume":"67","author":"GE Adams","year":"1976","unstructured":"Adams GE, Flockart IR, Smithen CE, Stratford IJ, Wardman P, Watts ME: Electron affinic radiosensitizers. VII. A correlation between structures, one-electron reduction potentials and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res 67: 9?20, 1976","journal-title":"Radiat Res"},{"key":"CR20","unstructured":"Brown JM, Lee WW: Pharmacokinetic considerations in radiosensitizer development. In: Brady LW (ed) Radiation Sensitizers. Cancer Management, Vol 5. Masson Publishing USA, 1980, pp2?13"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0167-8140(91)90199-Q","volume":"20","author":"D Chassagne","year":"1991","unstructured":"Chassagne D, Sancho-Garnier H, Charreau I, Eschwege F, Malaise EP: Progress report of a phase II and phase III trial with etanidazole (SR2508) - a multicentre European study. Radiother Oncol Suppl 20: 121?128, 1991","journal-title":"Radiother Oncol Suppl"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0167-8140(91)90200-Z","volume":"20","author":"TH Wasserman","year":"1991","unstructured":"Wasserman TH, Lee DJ, Cosmatos D, Coleman N, Phillips T, Davis L, Marcial V, Stetz J: Clinical trials with Etanidazole (SR-2508) by the radiation therapy oncology group (RTOG). Radiother Oncol Suppl 20: 129?136, 1991","journal-title":"Radiother Oncol Suppl"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/0360-3016(86)90230-0","volume":"12","author":"I Ahmed","year":"1986","unstructured":"Ahmed I, Jenkins TC, Walling JM, Stratford IJ, Sheldon PW, Adams GE, Fielden EM: Analogues of RSU1069: Radiosensitization and toxicityin vitro andin vivo. Int J Radiat Oncol Biol Phys 12: 1079?1081, 1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/bjc.1986.128","volume":"53","author":"RP Hill","year":"1986","unstructured":"Hill RP, Gulyas S, Whitmore GF: Studies of thein vivo andin vitro cytotoxicity of the drug RSU1069. Br J Cancer 53: 743?748, 1986","journal-title":"Br J Cancer"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/09553008914550451","volume":"55","author":"IJ Stratford","year":"1989","unstructured":"Stratford IJ, Adams GE, Godden J, Howells N: Induction of tumour hypoxia post-irradiation: A method for increasing the sensitizing efficiency of misonidazole and RSU1069in vivo. Int J Radiat Biol 55: 411?422, 1989","journal-title":"Int J Radiat Biol"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-1-4615-3768-7_18","volume-title":"Selective Activation of Drugs by Redox Processes. NATO Advanced Research Workshop Series","author":"IJ Stratford","year":"1990","unstructured":"Stratford IJ, Adams GE, Bremner JCM, Ding L, Edwards HE, Keohane A, Stephens MA: The assessment of bioreductive drug toxicityin vitro andin vivo. In: Adams GE, Breccia A, Fielden EM, Wardman P (eds) Selective Activation of Drugs by Redox Processes. NATO Advanced Research Workshop Series. Plenum Press, New York, 1990, pp203?212"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/0360-3016(86)90262-2","volume":"12","author":"GF Whitmore","year":"1986","unstructured":"Whitmore GF, Gulyas S: Studies on the toxicity of RSU1069. Int J Radiat Oncol Biol Phys 12: 1219?1222, 1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/0006-2952(87)90239-5","volume":"36","author":"P O'Neill","year":"1987","unstructured":"O'Neill P, McNeil SS, Jenkins TC: Induction of DNA crosslinksin vitro upon reduction of the nitroimidazole-aziridines RSU1069 and RSU1131. Biochem Pharmac 36: 1787?1791, 1987","journal-title":"Biochem Pharmac"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0360-3016(89)90896-1","volume":"16","author":"P O'Neill","year":"1989","unstructured":"O'Neill P, Cunniffe SMT: Assessment of the repair and damage of DNA induced by parent and reduced RSU-1069, a 2-nitroimidazole-aziridine. Int J Radiat Oncol Biol Phys 16: 963?966, 1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR30","first-page":"53","volume-title":"Selective Activation of Drugs by Redox Processes. NATO Advanced Research Workshop Series","author":"P O'Neill","year":"1990","unstructured":"O'Neill P, Jenner TJ, Sapora O, Crump PW, Cunniffe SMT, Fielden EM: The role of DNA damage in the bioreductive action of 2-nitroimidazoles. In: Adams GE, Breccia A, Fielden EM, Wardman P (eds) Selective Activation of Drugs by Redox Processes. NATO Advanced Research Workshop Series. Plenum Press, New York, 1990, pp53?61"},{"key":"CR31","first-page":"893","volume":"16","author":"MI Walton","year":"1986","unstructured":"Walton MI, Wolf CR, Workman P: Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 16: 893, 1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/0360-3016(86)90233-6","volume":"12","author":"DJ Chaplin","year":"1986","unstructured":"Chaplin DJ, Durand RE, Stratford IJ, Jenkins TC: The radiosensitizing and cytotoxic effects of RSU1069 on hypoxic cells in a murine tumour. Int J Radiat Oncol Biol Phys 12: 1091?1095, 1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1259\/0007-1285-59-708-1238","volume":"59","author":"A Horwich","year":"1986","unstructured":"Horwich A, Holliday SB, Deacon JM, Peckham MJ: A toxicity and pharmacokinetic study in man of the hypoxic cell radiosensitizer, RSU1069. Br J Radiol 59: 1238?1240, 1986","journal-title":"Br J Radiol"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0360-3016(92)90508-F","volume":"22","author":"EM Fielden","year":"1992","unstructured":"Fielden EM, Adams GE, Cole S, Naylor MA, O'Neill P, Stephens MA, Stratford IJ: Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugs. Int J Radiat Oncol Biol Phys 22: 707?711, 1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1021\/jm00171a040","volume":"33","author":"TC Jenkins","year":"1990","unstructured":"Jenkins TC, Naylor MA, O'Neill P, Threadgill MD, Cole S, Stratford IJ, Adams GE, Fielden EM Suto MJ, Stier MA: Synthesis and evaluation of ?-[[(2-Haloethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of ?-[(1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol (RSU1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J Med Chem 33: 2603?2610, 1990","journal-title":"J Med Chem"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/bjc.1976.78","volume":"33","author":"JL Foster","year":"1976","unstructured":"Foster JL, Conroy PJ, Searle AJ, Willson RL: Metronidazole (Flagyl): characterization as a cytotoxic drug specific for hypoxic tumour cells. Br J Cancer 33: 485?490, 1976","journal-title":"Br J Cancer"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/bjc.1986.233","volume":"54","author":"DJ Chaplin","year":"1986","unstructured":"Chaplin DJ: Potentiation of RSU1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT). Br J Cancer 54: 727?731, 1986","journal-title":"Br J Cancer"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0360-3016(87)90075-7","volume":"13","author":"DJ Chaplin","year":"1987","unstructured":"Chaplin DJ, Acker B: Potentiation of RSU1069 tumour cytotoxicity by hydralazine: a new approach to selective therapy. Int J Radiat Oncol Biol Phys 13: 579?585, 1987","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0360-3016(92)90872-F","volume":"22","author":"S Cole","year":"1990","unstructured":"Cole S, Stratford IJ, Fielden EM, Adams GE, Leopold W, Elliott W, Suto M, Sebolt-Leopold J: Dual function nitroimidazoles less toxic than RSU1069: selection of candidate drugs for clinical trial (RB6145 and\/or PD130908). Int J Radiat Oncol Biol Phys 22: 545?548, 1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0360-3016(91)90787-5","volume":"21","author":"S Cole","year":"1991","unstructured":"Cole S, Stratford IJ, Bowler J, Nolan J, Wright EG, Lorimore SA, Adams GE: Oral (p.o.) dosing with RSU1069 and RB6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (i.p.) administration in mice. Int J Radiat Oncol Biol Phys 21: 387?395, 1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0360-3016(92)90872-F","volume":"22","author":"S Cole","year":"1992","unstructured":"Cole S, Stratford IJ, Fielden EM, Adams GE, Leopold W, Elliott W, Suto M, Sebolt-Leopold J: Dual function nitroimidazoles less toxic than RSU1069: selection of candidate drugs for clinical trial (RB6145 and\/or PD130908). Int J Radiat Oncol Biol Phys 22: 545?548, 1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR42","first-page":"232","volume-title":"Radiation Sensitizers","author":"JJ Clement","year":"1980","unstructured":"Clement.JJ, Wodinsky I, Johnson RK, Silveira DM: Radiosensitization and pharmacokinetics of oral and intraperitoneal misonidazole and desmethylmisonidazole in murine tumours. In: Brady LW (ed) Radiation Sensitizers. Masson Publishing, New York, 1980: 232?238"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0360-3016(82)90654-X","volume":"8","author":"CN Coleman","year":"1982","unstructured":"Coleman CN, Lee WW, Constine LS, Brown JM: The development of an oral pro-drug, SR-2545 of the 2-nitroimidazole radiosensitizer SR 2508. Int J Radiat Oncol Biol Phys 8: 431?434, 1982","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF00254231","volume":"22","author":"MI Walton","year":"1988","unstructured":"Walton MI, Workman P: Pharmacokinetics and metabolism of the mixed function hypoxic cell sensitizer prototype RSU1069 in mice. Cancer Chemother Pharmacol 22: 275?288, 1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF00686334","volume":"29","author":"M Binger","year":"1991","unstructured":"Binger M, Workman P: Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB6145) of the mixed-function hypoxic cell sensitizer\/cytotoxin a-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU1069). Cancer Chemother Pharmacol 29: 37?47, 1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0360-3016(92)90873-G","volume":"22","author":"JS Sebolt-Leopold","year":"1992","unstructured":"Sebolt-Leopold JS, Vincent PW, Benings KA, Elliott WL, Leopold WR, Stier MA, Suto MJ: Pharmacologic\/pharmacokinetic evaluation of emesis induced by analogues of RSU1069 and its control by anti-emetic drugs. Int J Radiat Oncol Biol Phys 22: 549?551, 1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/09553009114552071","volume":"60","author":"DJ Chaplin","year":"1991","unstructured":"Chaplin DJ: The effect of therapy on tumour vascular function. Int J Radiat Biol 60: 311?325, 1991","journal-title":"Int J Radiat Biol"},{"key":"CR48","first-page":"571","volume":"48","author":"J Denekamp","year":"1975","unstructured":"Denekamp J, Harris SR: Tests on two electron affinic radiosensitizersin vivo using regrowth of an experimental carcinoma. Br J Radiol 48: 571, 1975","journal-title":"Br J Radiol"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/bjc.1990.161","volume":"61","author":"JCM Bremner","year":"1990","unstructured":"Bremner JCM, Stratford IJ, Bowler J, Adams GE: Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer 61: 717?721, 1990","journal-title":"Br J Cancer"},{"key":"CR50","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/09553008914551781","volume":"56","author":"S Cole","year":"1989","unstructured":"Cole S, Stratford IJ, Adams GE: Manipulation of oxygenation in a human melanoma xenograft to exploit the bioreductive toxicity of RSU1069. Int J Radiat Biol 56: 587, 1989","journal-title":"Int J Radiat Biol"},{"key":"CR51","doi-asserted-by":"crossref","unstructured":"Chaplin DJ: Postirradiation modification of tumour bloodflow: a method to increase the effectiveness of chemical radiosensitizers. Radiat Res 292, 1988","DOI":"10.2307\/3577165"},{"key":"CR52","first-page":"719","volume-title":"Radiation Research","author":"JM Brown","year":"1987","unstructured":"Brown JM: Exploitation of bioreductive agents with vasoactive drugs. In: Fielden EM, Fowler JF, Hendry JH, Scott D (eds) Radiation Research, Vol 2. Taylor and Francis, London, 1987, pp 719?724"},{"key":"CR53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/02656738909140442","volume":"5","author":"MR Horsman","year":"1989","unstructured":"Horsman MR, Christensen KL, Overgaard J: Hydralazine induced enhancement of hyperthermic damage in the C3H mammary carcinomain vivo. Int J Hyperthermia 5: 123?136, 1989","journal-title":"Int J Hyperthermia"},{"key":"CR54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0167-8140(91)90145-7","volume":"20","author":"M Guichard","year":"1991","unstructured":"Guichard M, Lespinasse F, Trotter M, Durand R, Chaplin DG: The effect of hydralazine on blood flow and misonidazole toxicity in human tumour xenografts. Radiother Oncol 20: 117?123, 1991","journal-title":"Radiother Oncol"},{"key":"CR55","doi-asserted-by":"crossref","unstructured":"Jirtle RL: Chemical modification of tumour blood flow. Int J Hyperthermia 4: 355?371","DOI":"10.3109\/02656738809016490"},{"key":"CR56","doi-asserted-by":"crossref","unstructured":"Honness D, Bleehen NM: Effect of two tumour blood flow modifiers in KHT tumour and normal tissue in mice. In: Moore JV, West DC (eds) Vasculature as a target for anticancer therapy. 16th L.H. Gray Conference Proceedings, 1991, pp249?253","DOI":"10.1080\/09553009114551951"},{"key":"CR57","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/bjc.1988.177","volume":"58","author":"IJ Stratford","year":"1988","unstructured":"Stratford IJ, Adams GE, Godden J, Howells N, Nolan J, Timpson N: Potentiation of the anti-tumour effect of melphalan by the vaso-active drug hydralazine. Br J Cancer 58: 122?127, 1988","journal-title":"Br J Cancer"},{"key":"CR58","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0014-5793(89)80655-6","volume":"249","author":"JF Dunn","year":"1989","unstructured":"Dunn JF, Frostick S, Adams GE, Stratford IJ, Howells N, Hogan G, Radda GK: Induction of tumour hypoxia by a vasoactive agent: A combined NMR and radiobiological study. FEBS Lett 249: 343?347, 1989","journal-title":"FEBS Lett"},{"key":"CR59","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/bjc.1990.161","volume":"61","author":"JCM Bremner","year":"1990","unstructured":"Bremner JCM, Stratford IJ, Bowler J, Adams GE: Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer 61: 717?721, 1990","journal-title":"Br J Cancer"},{"key":"CR60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-4615-3768-7_20","volume-title":"Selective Activation of Drugs by Redox Processes","author":"DG Hirst","year":"1990","unstructured":"Hirst DG, Hill SA: The control of tumour oxygenation in mice: the importance of tumour site. In: Adams GE, Breccia A, Fielden EM, Wardman P (eds) Selective Activation of Drugs by Redox Processes. Plenum Press, New York, 1990, pp223?228"},{"key":"CR61","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/09553009114551861","volume":"60","author":"DG Hirst","year":"1991","unstructured":"Hirst DG, Hirst VK, Shaffi KM, Prise VE, Joiner B: The influence of vasoactive agents on the perfusion of tumours growing in three sites in the mouse. Int J Radiat Biol 60:211?218, 1991","journal-title":"Int J Radiat Biol"},{"key":"CR62","first-page":"297","volume-title":"Radiation Research","author":"B Acker","year":"1987","unstructured":"Acker B, Lentle B, Chaplin DJ: The effect of hydralazine on blood flow in human tumours. In: Fielden EM, Fowler JF, Hendry JH, Scott D (eds) Radiation Research, Vol 1. Taylor and Francis, London, 1987, p297"},{"key":"CR63","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0167-8140(90)90108-9","volume":"18","author":"NP Rowell","year":"1990","unstructured":"Rowell NP, Flower MA, McCready VR, Cronin B, Horwich A: The effects of single dose oral hydralazine on blood flow through human lung tumours. Radiother Oncol 18: 283?292, 1990","journal-title":"Radiother Oncol"},{"key":"CR64","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1476-5381.1984.tb10775.x","volume":"82","author":"CR Beddell","year":"1984","unstructured":"Beddell CR, Goodford PJ, Kneen G, White RD, Wilkinson S, Wooton R: Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. Br J Pharmacol 82: 397?401, 1984","journal-title":"Br J Pharmacol"},{"key":"CR65","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/0360-3016(86)90158-6","volume":"12","author":"GE Adams","year":"1986","unstructured":"Adams GE, Barnes DHW, DuBoulay C, Loutit JF, ColeS, Sheldon PW, Stratford IJ, van den Aardweg GJMJ, Hopewell JW, White RD, Kneen G, Nethersell ABW, Edwards JC: Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of hemoglobin - implications for therapy. Int J Radiat Oncol Biol Phys 12: 1299?1302, 1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR66","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/0360-3016(89)90278-2","volume":"16","author":"GE Adams","year":"1989","unstructured":"Adams GE, Stratford IJ, Nethersell ABW, White RD: Induction of severe tumour hypoxia by the modifiers of oxygen affinity of hemoglobin. Int J Radiat Oncol Biol Phys 16: 1179?1182, 1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 1","key":"CR67","first-page":"621","volume":"16","author":"P Bedford","year":"1990","unstructured":"Bedford P, Nethersell ABW, Stratford IJ, Cole S, Bremner JCM,Adams GE: Potentiation of bioreductive drugs by BW12c. J Canc Res Clin Oncol 16: (suppl 1): 621, 1990","journal-title":"J Canc Res Clin Oncol"},{"key":"CR68","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/0360-3016(89)90280-0","volume":"16","author":"D Honness","year":"1989","unstructured":"Honness D, White RD, Nethersell ABW, Bleehen NM: Effects of the manipulation of oxyhemoglobin status by BW12c on tumour thermosensitivity and on blood flow in tumour and normal tissue in mice. Int J Radiat Oncol Biol Phys 16: 1187?1191, 1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR69","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/09553009114552151","volume":"60","author":"JCM Bremner","year":"1991","unstructured":"Bremner JCM, Counsell CJR, Edwards HE, Stratford IJ, Adams GE, Nethersell ABW, Bedford P: Monitoring metabolic responses after induction of hypoxia in the KHT tumour using31PNMR spectroscopy. Int J Radiat Biol 60: 363?367, 1991","journal-title":"Int J Radiat Biol"},{"key":"CR70","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0167-8140(89)90023-6","volume":"16","author":"S Cole","year":"1989","unstructured":"Cole S, Robbins L: Manipulation of oxygenation in a human tumour xenograft with BW12c or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU1069. Radiother Oncol 16: 235, 1989","journal-title":"Radiother Oncol"},{"key":"CR71","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1073\/pnas.72.9.3666","volume":"72","author":"EA Carswell","year":"1975","unstructured":"Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis in tumours. Proc Natl Acad Sci USA 72: 3669?3670, 1975","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR72","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/0277-5379(87)90157-X","volume":"23","author":"GP Smith","year":"1987","unstructured":"Smith GP, Calveley SB, Smith MJ, Baguley BC: Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol 23: 1209?1211,1987","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR73","first-page":"6011","volume":"48","author":"PG Braunschweiger","year":"1988","unstructured":"Braunschweiger PG, Johnson CS, Kumar N, Ord V, Furmanski P: Anti-tumour effects of recombinant human interleukin 1a in RIF-1 and PancO2 solid tumours. Cancer Res 48:6011?6016, 1988","journal-title":"Cancer Res"},{"key":"CR74","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/09553009114552231","volume":"60","author":"MC Bibby","year":"1991","unstructured":"Bibby MC, Double JA, Phillips RM, Quinn PKM: Flavone acetic acid: is vascular shutdown the crucial mechanism of action? Int J Radiat Biol 60: 395?399, 1991","journal-title":"Int J Radiat Biol"},{"key":"CR75","first-page":"3707","volume":"47","author":"T Manda","year":"1987","unstructured":"Manda T, Shimomura K, Mukumoto S, Kobayashi K, Mizota T, Hirai O, Matsumoto S, Oku T, Nishigaki F, Mori J, Kikuchi H: Recombinant human tumour necrosis factor - a: evidence of an indirect mode of anti-tumour activity. Cancer Res 47: 3707?3711, 1987","journal-title":"Cancer Res"},{"key":"CR76","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/jnci\/80.4.241","volume":"80","author":"GJ Finlay","year":"1988","unstructured":"Finlay GJ, Smith GP, Fray LM, Baguley BC: Effects of flavone acetic acid (NSC347512) on Lewislung carcinoma: evidence of an indirect effect. J Nat Cancer Inst 80: 241?245, 1988","journal-title":"J Nat Cancer Inst"},{"key":"CR77","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/09553009114550381","volume":"59","author":"HE Edwards","year":"1991","unstructured":"Edwards HE, Bremner JCM, Stratford IJ: Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid. Int J Radiat Biol 59: 419?432, 1991","journal-title":"Int J Radiat Biol"},{"key":"CR78","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/09553009114552181","volume":"60","author":"HE Edwards","year":"1991","unstructured":"Edwards HE, Bremner JCM, Stratford IJ: Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs. Int J Radiat Biol 60: 373?377, 1991","journal-title":"Int J Radiat Biol"},{"key":"CR79","first-page":"128","volume":"24","author":"IJ Stratford","year":"1992","unstructured":"Stratford IJ: Bioreductive drugs in cancer therapy. Br J Radiol Suppl 24: 128?136, 1992","journal-title":"Br J Radiol Suppl"},{"key":"CR80","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/bjc.1989.230","volume":"60","author":"DJ Kerr","year":"1989","unstructured":"Kerr DJ, Maughan T, Newland E, Rustin G, Bleehen NM, Lewis C: Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal cancer.Br J Cancer 60: 104?106, 1989","journal-title":"Br J Cancer"},{"key":"CR81","first-page":"413","volume":"81","author":"BC Baguley","year":"1990","unstructured":"Baguley BC, Denny WA, Atwell GJ, Rewcastle GW, Ching LM, Thomsen LL, Zhuang L: Synthesis and properties of a new analogue of flavone acetic acid: 5,6-dimethyl xanthenone-4-acetic acid. Proc Am Assoc Cancer Res 81: 413, 1990","journal-title":"Proc Am Assoc Cancer Res"},{"key":"CR82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1751-1097.1992.tb04222.x","volume":"55","author":"BW Henderson","year":"1992","unstructured":"Henderson BW, Dougherty TJ: How does photodynamic therapy work? Photochem Photobiol 55: 145?157, 1992","journal-title":"Photochem Photobiol"},{"key":"CR83","first-page":"572","volume":"45","author":"BW Henderson","year":"1985","unstructured":"Henderson BW, Waldow SM, Mang TS, Potter WR, Malone PB, Dougherty TJ: Tumour destruction and kinetics of tumour cell death in two experimental mouse tumours following photodynamic therapy. Cancer Res 45: 572?576, 1985","journal-title":"Cancer Res"},{"key":"CR84","first-page":"2326","volume":"36","author":"KR Weishaupt","year":"1976","unstructured":"Weishaupt KR, Gomer CJ, Dougherty TJ: Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumour. Cancer Res 36: 2326?2329, 1976","journal-title":"Cancer Res"},{"key":"CR85","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1751-1097.1986.tb05648.x","volume":"43","author":"JD Spikes","year":"1986","unstructured":"Spikes JD: Phthalocyanines as photosensitizers in biological systems and for the photodynamic therapy of tumours. Photochem Photobiol 43:691?699, 1986","journal-title":"Photochem Photobiol"},{"key":"CR86","first-page":"279","volume-title":"Photodynamic Therapy of Neoplastic Disease","author":"JE Leir van","year":"1990","unstructured":"van Leir JE: Phthalocyanines as sensitizers for PDT of cancer. In: Kessel D (ed) Photodynamic Therapy of Neoplastic Disease. Vol 1. CRC Press,Boston,1990, pp279?289"},{"key":"CR87","first-page":"2858","volume":"46","author":"S Gonzalez","year":"1986","unstructured":"Gonzalez S, Arnfield MR, Meeker BE, Tulip J, Lakey WH, Chapman JD: Treatment of Dunning R3327-AT rat prostate tumours with photodynamic therapy in combination with misonidazole. Cancer Res 46: 2858?2862,1986","journal-title":"Cancer Res"},{"key":"CR88","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1751-1097.1990.tb04201.x","volume":"52","author":"G Jori","year":"1990","unstructured":"Jori G: Photosensitized processes in vivo: Proposed phototherapeutic applications. Photochem Photobiol 52: 439?444, 1990","journal-title":"Photochem Photobiol"},{"key":"CR89","first-page":"263","volume-title":"Photodynamic Therapy of Neoplastic Disease","author":"CJ Tralau","year":"1990","unstructured":"Tralau CJ, Barr H, MacRobert AJ, Bown SG: Relative merits of porphyrin and phthalocyanine sensitization for photodynamic therapy.In: Kessel D (ed) Photodynamic Therapy of Neoplastic Disease. Vol 1. CRC Press, Boston, 1990, pp263?277"},{"key":"CR90","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/bjc.1991.417","volume":"64","author":"AJ Pope","year":"1991","unstructured":"Pope AJ, MacRobert AJ, Phillips D, Bown SG: The detection of phthalocyanine fluorescence in normal rat bladder wall using sensitive digital imaging microscopy. Br J Cancer 64: 875?879, 1991","journal-title":"Br J Cancer"},{"key":"CR91","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/bjc.1992.412","volume":"66","author":"JCM Bremner","year":"1992","unstructured":"Bremner JCM, Adams GE, Pearson JK, Sansom JM, Stratford IJ, Bedwell J, Bown SG, MacRobert AJ, Phillips D: Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145. Br J Cancer 66: 1070?1076,1992","journal-title":"Br J Cancer"},{"key":"CR92","first-page":"1681","volume":"50","author":"W Mueller-Kleiser","year":"1990","unstructured":"Mueller-Kleiser W, Schaefer C, Walenta S, Rofstad EK, Fenton BM,Sutherland RM: Assessment of tumour energy and oxygenation status by bioluminescence, nuclear magnetic resonance spectroscopy and cryospectrophotometry. Cancer Res 50: 1681?1690, 1990","journal-title":"Cancer Res"},{"key":"CR93","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2307\/3577798","volume":"120","author":"P Vaupel","year":"1989","unstructured":"Vaupel P, Okunieff P, Kallinowski F, Neuringer LJ: Correlation between 31P-NMR spectroscopy and tissue O2 tension measurements in a murine fibrosarcoma. Radiat Res 120: 477?485, 1989","journal-title":"Radiat Res"},{"key":"CR94","first-page":"137","volume":"24","author":"GE Adams","year":"1992","unstructured":"Adams GE, Bremner JCM, Stratford, IJ, Wood PJ: Can31P magnetic resonance spectroscopy measurements of changes in experimental tumour metabolism be related to modification of oxygen status? Br J Radiol Suppl 24: 137?141, 1992","journal-title":"Br J Radiol Suppl"},{"key":"CR95","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/bjc.1991.414","volume":"64","author":"JCM Bremner","year":"1991","unstructured":"Bremner JCM, Counsell CJR, Adams GE, Stratford IJ, Wood PJ, Dunn JF, Radda GK:In vivo 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modification. Br J Cancer 64: 862?866, 1991","journal-title":"Br J Cancer"},{"key":"CR96","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0360-3016(92)90856-D","volume":"22","author":"PJ Wood","year":"1992","unstructured":"Wood PJ, Stratford IJ, Sansom JM, Cattanach BM, Quinney RM, Adams GE: The response of spontaneous and transplantable murine tumours to vasoactive agents measured by31P magnetic resonance spectroscopy.Int J Radiat Oncol Biol Phys 22: 473?476, 1992","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00689809.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00689809\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00689809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T12:09:26Z","timestamp":1586002166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00689809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,6]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1993,6]]}},"alternative-id":["BF00689809"],"URL":"https:\/\/doi.org\/10.1007\/bf00689809","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,6]]}}}